ClinicalTrials.gg
CompletedNCT06384313Updated Oct 28, 2026

Butyrate-enriched Triglyceride and Diabetes Prevention

An interventional study of butyrate/hexanoate-enriched triglycerides in Type 2 Diabetes, PreDiabetes and Obesity, sponsored by Maastricht University Medical Center. Completed at 1 site in Netherlands. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Basic science

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center — 2 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Maastricht University Medical Center.

Enrollment
10th of 36
44 · median 31
Started
2024
with 2 others
No phase
34 of 40
2 open now
Registered
38th of 40
by date

Among the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center, this one is the 10th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2024, is one of 34 with no phase, and was the 38th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center, or all of them as a file.
02

Study summary

A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control, inflammation, and insulin resistance. Even though the SCFA hexanoate is less researched, it has been shown to be involved in anti-inflammatory processes. Of note, acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation. It has been shown that a butyrate/hexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time. Yet, it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits. In this study it is hypothesized that a chronic increase of butyrate/hexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function, reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweight/obesity and prediabetes.

03

Conditions studied

  • Type 2 Diabetes
  • PreDiabetes
  • Obesity
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  • Age 20-70 years
  • ≥ 28 and \< 40 kg/m2
  • Weight stable for at least 3 months
  • Normal blood pressure (systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg)
  • One or more of the following criteria to determine disturbed glucose/insulin homeostasis

    • Fasting glucose 5.6-6.9 mmol/L
    • Two-hour glucose of 7.8-11.1 mmol/L
    • HOMA-IR ≥ 2.2
    • (5.7-6.4%)

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus (type 1 or 2)

    • Cardiovascular disease: including no history or myocardial infarction, heart failure, arrhythmias
    • Pulmonary disease: no history of , emphysema, bronchitis, asthma
    • Kidney (e.g. kidney failure) or liver (e.g. cirrhosis, non-alcoholic fatty acid) malfunction
    • Gastrointestinal disease (no inflammatory bowel disease, irritable bowel syndrome or digestive disorders) or a history of abdominal surgery (except appendectomy and cholecystectomy)
    • disease
    • Any other diseases affecting glucose and/or lipid metabolism or use of any medication that influence glucose or fat metabolism and inflammation
    • Ongoing disease or any disease with a ≤ 5 years
    • Abuse of products; alcohol (>15 units per week) and drugs, excessive nicotine use defined as >20 cigarettes per week
    • Regular supplementation of pre- or probiotic products, use of pre- or probiotics, antibiotics and laxatives 3 months prior to the start of the study
    • Intensive exercise training more than three hours a week
    • Plan to lose weight or to follow a hypocaloric diet or vegetarian diet
    • Pregnancy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    butyrate/hexanoate-enriched triglycerides

    Oil containing butyrate and hexanoate-enriched triglycerides

    Dietary Supplement: butyrate/hexanoate-enriched triglycerides

  • Placebo comparator
    placebo

    Oil devoid of butyrate and hexanoate but with similar composition as the intervention oil

    Dietary Supplement: butyrate/hexanoate-enriched triglycerides

Interventions

  • Dietary supplementbutyrate/hexanoate-enriched triglycerides

    The oils are consumed two times a day for 24 weeks (six months).

06

What researchers measure

Primary outcomes

  1. Peripheral insulin sensitivity

    The change of peripheral insulin sensitivity as assessed by a hyperinsulinaemic-euglycemic clamp

    Time frame: Before and 6 months after the start of the intervention

Secondary outcomes

  1. hepatic insulin sensitivity

    The change in hepatic insulin sensitivity as assessed by a hyperinsulinaemic-euglycemic clamp

    Time frame: Before and 6 months after the start of the intervention

  2. adipose tissue insulin sensitivity

    The change in adipose tissue insulin sensitivity as assessed by a hyperinsulinaemic-euglycemic clamp

    Time frame: Before and 6 months after the start of the intervention

  3. Energy expenditure (indirect calorimetry)

    The change in energy expenditure as measured via ventilated hood system

    Time frame: Before and 6 months after the start of the intervention

  4. Substrate oxidation (indirect calorimetry)

    The change in substrate oxidation as measured via ventilated hood system

    Time frame: Before and 6 months after the start of the intervention

  5. circulating SCFA

    The change in concentrations of circulating SCFA

    Time frame: Before and 6 months after the start of the intervention

  6. Faecal SCFA

    The change in concentrations of faecal SCFA

    Time frame: Before and 6 months after the start of the intervention

  7. Faecal microbiota composition

    The change in faecal microbiota composition assessing abundances of bacteria and diversity indices as assessed via 16s rRNA gene

    Time frame: Before and 6 months after the start of the intervention

  8. Circulating hormones such as insulin

    The change in concentrations of circulating hormones in peripheral blood

    Time frame: Before and 6 months after the start of the intervention

  9. Circulating metabolites such as glucose

    The change in concentrations of metabolites in peripheral blood

    Time frame: Before and 6 months after the start of the intervention

  10. body composition

    The change in body composition as assessed using DEXA scans

    Time frame: Before and 6 months after the start of the intervention

  11. body weight

    The change in body weight in kg using a weight scale

    Time frame: Before and 6 months after the start of the intervention

  12. Gut permeability

    The change in gut permeability as assessed using a multi-sugar test

    Time frame: Before and 6 months after the start of the intervention

07

Study locations

1 site
  • Maastricht University
    Maastricht, Limburg 5229 ER, Netherlands
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Sep 2026, 24 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 24 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Sep 2027 → Sep 2026 and completion Sep 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Sep 19, 2024
Primary completionActual
Sep 25, 2026was Sep 2027
CompletionActual
Sep 25, 2026was Sep 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Primary completion
Sep 1, 2027→Sep 25, 2026 (actual)
Oct 28, 2026
Study completion
Sep 1, 2027→Sep 25, 2026 (actual)
Oct 28, 2026
Enrollment
48 (estimated)→44 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Completed
    Primary completion Sep 1, 2027→Sep 25, 2026 (now actual)
    Study completion Sep 1, 2027→Sep 25, 2026 (now actual)
    Enrollment 48 (estimated)→44 (actual)
    + 7 other changes: identifiers, verification date, oversight details, site details, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06384313
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Sep 19, 2024
Primary completion
Sep 25, 2026
Completion
Sep 25, 2026
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion